Life sciences and diagnostics group Revvity has chosen Bruntwood SciTech’s Alderley Park as its newest UK hub.
The company joins over 250 innovative drug discovery, biotech, medcomms, diagnostics, AI, digital health and beauty tech businesses at the campus.
Revvity has secured a top research collaboration with Genomics England on the Generation Study, alongside NHS England.
The project seeks to screen up to 100,000 newborns and help inform decisions on using whole genome sequencing to screen for rare genetic conditions, advancing abilities for early detection.
Chris Hughes, managing director, North Europe at Revvity, said: “As our work with Genomics England enters an exciting new chapter, so do we. Our UK expansion is about more than simply establishing a presence; it’s about unlocking new opportunities for collaboration and innovation.
“With access to world-class lab infrastructure and unrivalled connectivity to the NHS collaborators and industry peers, our new Alderley Park base will be central to supporting the delivery of the Generation Study as one of the study’s extraction and sequencing collaborators.
“The Generation Study will help enable earlier diagnoses and better outcomes for newborns, while supporting our broader mission to push the boundaries of what’s possible in healthcare.”
The science and innovation campus by Bruntwood SciTech – a UK property platform dedicated to the growth of the innovation economy – is a joint venture between Bruntwood, L&G, and Greater Manchester Pension Fund.
Mark Julian, Bruntwood SciTech, said: “Supporting the growth of pioneering innovation businesses is central to our mission at Alderley Park. By delivering state-of-the-art workspace, tailored to specialist needs of companies like Revvity – alongside access to investment, skilled talent and potential collaborators – we can help these market-leading innovators grow and thrive, creating jobs and economic value across Cheshire and Greater Manchester.
“We’re thrilled to support not only Revvity’s UK growth, but also its collaboration with Genomics England. Their presence will strengthen our network of health innovators and make real world impactful changes to science, with benefits that will be felt far beyond Alderley Park.”
